GHP-88309 is an orally available non-nucleoside paramyxovirus polymerase inhibitor with broad-spectrum anti-paramyxoviral activity (EC50 in μM= 0.4/HPIV3-JS, 0.8/HPIV3-5F6, 2/SeV-F1R-eGF, 0.6/MeV/Alaska.USA 16.00, 0.4/CDV-5804p) and little cytoxicity (CC50 >20μM). GHP-88309 potently inhibits the replication of HPIV1 isolate 5F6 and HPIV3 isolates 10L3 & 9R4 in 3D-ALI-HBTEC human airway organoids (EC50 = 280,90, 105 nM, respectively) in 3D-ALI-HBTECs. HPIV3 and provides complete protection against lethal Sendai virus infection in mice (150 mg/kg bid. po. starting at time of infection or 48 hrs after), a murine surrogate model of human HPIV3 disease.
Orally available non-nucleoside paramyxovirus polymerase inhibitor with broad-spectrum anti-paramyxoviral activity in vitro and in vivo.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
Paramyxoviruses such as human parainfluenza virus type-3 (HPIV3) and measles virus (MeV) are a substantial health threat. In a high-throughput screen for inhibitors of HPIV3 (a major cause of acute respiratory infection), we identified GHP-88309-a non-nucleoside inhibitor of viral polymerase
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
